Zimmer, our Chief Scientific Officer has just bought 1,057,143 more shares (£370k). That is a substantial purchase. There are no certainties in life and I have seen directors get their purchases wrong - the trial is also double blinded - however a purchase of this size shows great personal confidence from him at this stage of the clinical trial in both Lupuzor and Immupharma.
They have raised £1m rather than £0.8m in the additional placing.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.